Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 300

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 300
---
 optionsand rights(a) |     |     | Weighted-averageexercise price ofstock options andrights$ |          |     | Number of shares of common stockremaining available for futureissuance under equity compensationplans (excluding securities reflectedin column (a))(2) |     |
| Equity compensation plans approved by security holders - 2017 Plan(1)                                                 |     |                                                                                                    | 236 |     |                                                           |    21.16 |     |                                                                                                                                                        | 129 |
| Equity compensation plans not approved by security holders - Del Mar (BC) 2013 Amended and Restated Stock Option Plan |     |                                                                                                    |   1 |     |                                                           | 2,175.08 |     |                                                                                                                                                        |   — |
| Totals                                                                                                                |     |                                                                                                    | 237 |     |                                                           |    32.92 |     |                                                                                                                                                        | 129 |

| (1) | The Del Mar (BC) 2013 Amended and Restated Stock Option Plan refers to the Company’s previous equity compensation plan. |

| (2) | The balance of91shares of common stock available for issuance under the 2017 Plan as of December 31, 2023, is net of stock options previously exercised. |

<div align='center'>F-6 1</div>

Kintara Therapeutics, Inc. Notes to Condensed Consolidated Interim Financial Statements (Unaudited) December 31, 2023 (expressed in US dollars and in thousands, except par value and per share amounts, unless otherwise noted)

The maximum number of shares of Company common stock with respect to which any one participant may be granted awards during any calendar year is 8 % of the Company’s fully diluted shares of common stock on the date of grant (excluding the number of shares of common stock issued under the 2017 Plan and/or the Legacy Plan or subject to outstanding awards granted under the 2017 Plan and/or the Legacy Plan). No award will be granted under the 2017 Plan on, or after, July 7, 2027.

Stock options

During the six months ended December 31, 2023, a total of 89 stock options to purchase shares of common stock at an exercise price of $ 4.655 per share were granted to directors and officers of the Company. The 26 options granted to non-employee directors vest pro rata monthly over 12 months commencing on December 31, 202